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We investigate the optimal vaccination and screening strategies to minimize human papillomavirus (HPV) associated morbidity
and the interventions cost. We propose a two-sex compartmental model of HPV-infection with time-dependent controls
(vaccination of adolescents, adults, and screening) which can act simultaneously. We formulate optimal control problems
complementing our model with two different objective functionals. The first functional corresponds to the protection of the
vulnerable group and the control problem consists of minimizing the cumulative level of infected females over a fixed time interval.
The second functional aims to eliminate the infection, and, thus, the control problem consists of minimizing the total prevalence
at the end of the time interval. We prove the existence of solutions for the control problems, characterize the optimal controls,
and carry out numerical simulations using various initial conditions. The results and properties and drawbacks of the model are
discussed.
1. Introduction
Human papillomavirus (HPV) is the leading etiological fac-
tor for the development of cervical cancer. According to
the World Health Organization (WHO) report, cervical
cancer is the fourth most frequent cancer in women with
approximately 570,000 new cases reported in 2018 [1]. This
fact makes the design, implementation, and maintenance of
effective preventing policies against cervical cancer a highly
relevant public health problem.This consideration motivates
research on the design and development of cost-effective
vaccination and screening programs against HPV infection.
On October 5th of 2018, the US Food and Drug Admin-
istration (FDA) approved the nonavalent vaccine Gardasil-9
against HPV infection for use in women and men aged 27
to 45 [2]. Earlier, the FDA approved the vaccine for persons
between the ages of 9 to 26. Gardasil-9 protects against
HPV types 6, 11, 16, and 18 (that are already targeted by the
quadrivalent HPV vaccine Gardasil) and against the next five
most common oncogenic viral types, namely, HPV 31, 33,
45, 52, and 58. These nine HPV types are responsible for the
majority of HPV-associated diseases [3]. In addition to the
nonavalent and quadrivalent vaccines, there is also an FDA-
approved bivalent vaccine (Cervarix) that targets HPV types
16 and 18.
The introduction of HPV vaccines is changing the epi-
demiology of cervical cancer and other HPV-associated
diseases each year. Since HPV-associated morbidity and
mortality are usually considerably higher in females than
in males, in the majority of countries the primary target
group of HPV vaccination programs is adolescent school
girls aged 9–14 [4]. However, considering that Gardasil-9 has
been licensed for a broader age range in both males and
females, it is essential to analyze the potential health benefits
of extending vaccination tomales, aswell as older individuals,
versus a higher economic cost of such programs.
To examine the dynamics of HPV spread and control,
numerous mathematical models have been proposed [5–
15]. While these and other recent studies analyzed different
strategies forHPVcontrol and brought important insight into
the problem, the majority of them did not take into account
the optimality of these interventions. The study of optimality,
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however, is of particular relevance in the allocation of limited
public health resources. In this context, the application of
optimal control theory has proven to be an important tool
for evaluating and optimizing various detection, prevention,
therapy, vaccination, and other intervention programs [16].
So far, to the best of authors’ knowledge, for the case
of HPV infection only a few studies have been done using
the optimal control framework to assess the impact of
vaccination programs [17, 18]. Brown andWhite [17] explored
how to target vaccination in the UK. This study highlights
the importance of including a catch-up vaccination policy
in order to control the spread of the infection. In a recently
published paper, Malik et al. [18] analyzed the optimal
control strategies for a vaccination program administering
the bivalent, quadrivalent, and nonavalent HPV vaccines to
the female population. In particular, they explored scenarios
where the three vaccines are used simultaneously compared
with the case where the bivalent and quadrivalent vaccines
were initially used and then, during the program, one or both
of them are replaced by the nonavalent vaccine.
Since there is evidence that switching from the quadriva-
lent to the nonavalent is likely to be cost-saving [3], in this
work we focus on the application of the nonavalent vaccine.
The aim is to use optimal control theory to gain insight
into the best combination of vaccination and screening to
reduce the spread of HPV infection, as well as the cost of
the intervention strategy. To address this issue, we construct a
mathematicalmodel that allows vaccination prior to and after
sexual initiation in both males and females. Moreover, we
also include into the model a screening program that allows
detection of HPV-associated diseases.
In general, public health interventions have two basic
objectives: protection of population groups that are at consid-
erably higher risk of contracting or developing severe disease
and total elimination of the infection when it is potentially
possible. Accordingly, in this paper, we consider both of these
objectives formulating two optimal control problems. Our
ultimate goal is to explore where control policies aimed at the
protection of the vulnerable group and at the eradication of
the infection differ.
The organization of this paper is as follows: The next
section is devoted to formulation and analysis of an epidemic
model for the transmission dynamics of HPV infection in a
heterosexual population. In Section 3, we propose optimal
control problems incorporating two objective functionals
and simultaneous application of several controls into our
model. In Section 4, we prove the existence of solutions and
characterization of the optimal controls via the Pontryagin
maximum principle. Section 5 contains the results of numer-
ical simulations of the model and the profiles of the optimal
controls. The last section contains the conclusions and a
discussion of the obtained results.
2. Model Formulation and Analysis
In this study, we propose and study a compartmental
model for the transmission dynamics of the HPV types
targeted by the nonavalent vaccine Gardasil-9. The model
classifies the hosts’ population at time 𝑡 denoted by 𝑁(𝑡)
according to gender and infection status. We subdivide the
total female population 𝑁𝑓(𝑡) into four mutually exclusive
compartments: unvaccinated susceptibles 𝑆𝑓(𝑡), vaccinated
susceptibles 𝑉𝑓(𝑡), and infectious females unaware𝑈𝑓(𝑡) and
aware 𝐼𝑓(𝑡) of their infection; thus
𝑁𝑓 (𝑡) = 𝑆𝑓 (𝑡) + 𝑉𝑓 (𝑡) + 𝑈𝑓 (𝑡) + 𝐼𝑓 (𝑡) . (1)
The total male population 𝑁𝑚(𝑡) consists of three compart-
ments: unvaccinated susceptibles 𝑆𝑚(𝑡), vaccinated suscepti-
bles 𝑉𝑚(𝑡), and infectious males 𝐼𝑚(𝑡), so that
𝑁𝑚 = 𝑆𝑚 (𝑡) + 𝑉𝑚 (𝑡) + 𝐼𝑚 (𝑡) . (2)
We assume that individuals enter the sexually active pop-
ulation as singles at a constant rateΛwith a sex ratio of 50:50.
Females and males leave the population by death or ceasing
sexual activity at per capita rates 𝜇𝑓 and 𝜇𝑚, respectively.
In this study, we distinguish between vaccinations prior and
after sexual initiation. In particular, a fraction 𝑤1 of females
and a fraction 𝑤2 of males are vaccinated before they enter
the sexually active class and thus are recruited into their
vaccinated compartment. Moreover, the susceptible sexually
active females and males are vaccinated at rates 𝑢1 and 𝑢2
per unit of time, respectively. The vaccine reduces the force
of infection by a factor 0 ≤ 𝜖 ≤ 1; thus, the vaccine is
completely effective when 𝜖 = 0 and ineffective when 𝜖 =1. Therefore 1 − 𝜖 is the vaccine effectiveness. The vaccine-
induced immunity wanes at a rate 𝜃. Both males and females
can clear the infection naturally with per capita rates 𝛾𝑚 and𝛾𝑓, respectively. No permanent immunity is assumed after
that.
Susceptible females become infected at a rate 𝛽𝑚 fol-
lowing effective contact with an infectious male. After the
acquisition of HPV infection, a fraction 𝑝 of the infected
females may develop symptoms and become aware of their
infection entering the 𝐼𝑓(𝑡) class. The remaining infected
females do not realize their infection and move to the
unaware class 𝑈𝑓(𝑡). However, the screening program may
allow the unaware infected females to detect their infection
at a rate 𝛼.
Susceptible males can be infected by unaware infected
females 𝑈𝑓(𝑡) at a rate 𝛽𝑓 and by aware infected females𝐼𝑓(𝑡) at a rate 𝛽𝑓. We assume that 0 < 𝛽𝑓 < 𝛽𝑓 since a
female conscious of her infection can take precautions like
condom use to reduce the possibility of transmission. Since
HPV infection is transmitted (in most cases) sexually, we
model the transmission via the standard incidence [22].
The model resulting from these assumptions is governed
by the following system of differential equations:
̇𝑆𝑓 = (1 − 𝑤1) Λ2 − 𝛽𝑚𝑆𝑓
𝐼𝑚𝑁𝑚 − 𝑢1𝑆𝑓 + 𝛾𝑓𝑈𝑓 + 𝛾𝑓𝐼𝑓
+ 𝜃𝑉𝑓 − 𝜇𝑓𝑆𝑓,
?̇?𝑓 = (𝑆𝑓 + 𝜖𝑉𝑓) (1 − 𝑝) 𝛽𝑚 𝐼𝑚𝑁𝑚 − (𝛾𝑓 + 𝛼)𝑈𝑓
− 𝜇𝑓𝑈𝑓,
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̇𝐼𝑓 = (𝑆𝑓 + 𝜖𝑉𝑓) 𝑝𝛽𝑚 𝐼𝑚𝑁𝑚 + 𝛼𝑈𝑓 − 𝛾𝑓𝐼𝑓 − 𝜇𝑓𝐼𝑓,
?̇?𝑓 = 𝑤1Λ2 + 𝑢1𝑆𝑓 − 𝜖𝛽𝑚𝑉𝑓
𝐼𝑚𝑁𝑚 − (𝜇𝑓 + 𝜃)𝑉𝑓,
̇𝑆𝑚 = (1 − 𝑤2) Λ2 − (𝛽𝑓
𝑈𝑓𝑁𝑓 + 𝛽𝑓
𝐼𝑓𝑁𝑓)𝑆𝑚 − 𝑢2𝑆𝑚
+ 𝛾𝑚𝐼𝑚 + 𝜃𝑉𝑚 − 𝜇𝑚𝑆𝑚,
̇𝐼𝑚 = (𝛽𝑓 𝑈𝑓𝑁𝑓 + 𝛽𝑓
𝐼𝑓𝑁𝑓) (𝑆𝑚 + 𝜖𝑉𝑚) − (𝛾𝑚 + 𝜇𝑚) 𝐼𝑚,
?̇?𝑚 = 𝑤2Λ2 − (𝛽𝑓
𝑈𝑓𝑁𝑓 + 𝛽𝑓
𝐼𝑓𝑁𝑓) 𝜖𝑉𝑚 + 𝑢2𝑆𝑚
− (𝜇𝑚 + 𝜃)𝑉𝑚,
(3)
where all the parameters are assumed to be nonnegative.
We are interested in the dynamics of model (3) over
a finite time interval [0, 𝑇]. Therefore, we assume that the
population for both sexes is constant with values𝑁𝑓 = Λ/2𝜇𝑓
and 𝑁𝑚 = Λ/2𝜇𝑚. This assumption is reasonable since the
epidemic process is considerably faster than the demographic
one over a short period of time.
Under the constant population assumption, we can
express system (3) in terms of the proportions
𝑆𝑓 = 𝑆𝑓𝑁𝑓 , 𝑈𝑓 =
𝑈𝑓𝑁𝑓 , 𝐼𝑓 =
𝐼𝑓𝑁𝑓 ,
𝑉𝑓 = 𝑉𝑓𝑁𝑓 , 𝑆𝑚 =
𝑆𝑚𝑁𝑚 , 𝐼𝑚 =
𝐼𝑚𝑁𝑚 .
(4)
Omitting the bars above the variables for convenience, our
normalized system becomes
̇𝑆𝑓 = (1 − 𝑤1) 𝜇𝑓 − 𝛽𝑚𝑆𝑓𝐼𝑚 + 𝛾𝑓𝑈𝑓 + 𝛾𝑓𝐼𝑓 + 𝜃𝑉𝑓
− (𝑢1 + 𝜇𝑓) 𝑆𝑓,
?̇?𝑓 = (𝑆𝑓 + 𝜖𝑉𝑓) (1 − 𝑝) 𝛽𝑚𝐼𝑚 − (𝛾𝑓 + 𝛼)𝑈𝑓 − 𝜇𝑓𝑈𝑓,
̇𝐼𝑓 = (𝑆𝑓 + 𝜖𝑉𝑓) 𝑝𝛽𝑚𝐼𝑚 + 𝛼𝑈𝑓 − 𝛾𝑓𝐼𝑓 − 𝜇𝑓𝐼𝑓,
?̇?𝑓 = 𝑤1𝜇𝑓 + 𝑢1𝑆𝑓 − 𝜖𝛽𝑚𝑉𝑓𝐼𝑚 − (𝜇𝑓 + 𝜃)𝑉𝑓,
̇𝑆𝑚 = (1 − 𝑤2) 𝜇𝑚 − (𝛽𝑓𝑈𝑓 + 𝛽𝑓𝐼𝑓) 𝑆𝑚 + 𝛾𝑚𝐼𝑚 + 𝜃𝑉𝑚
− (𝑢2 + 𝜇𝑚) 𝑆𝑚,
̇𝐼𝑚 = (𝛽𝑓𝑈𝑓 + 𝛽𝑓𝐼𝑓) (𝑆𝑚 + 𝜖𝑉𝑚) − (𝛾𝑚 + 𝜇𝑚) 𝐼𝑚,
?̇?𝑚 = 𝑤2𝜇𝑚 − (𝛽𝑓𝑈𝑓 + 𝛽𝑓𝐼𝑓) 𝜖𝑉𝑚 + 𝑢2𝑆𝑚
− (𝜇𝑚 + 𝜃)𝑉𝑚.
(5)
Please note that system (5) always has a unique disease-
free equilibrium 𝐸0 = (𝑆∗𝑓, 𝑈∗𝑓 , 𝐼∗𝑓 , 𝑉∗𝑓 , 𝑆∗𝑚, 𝐼∗𝑚, 𝑉∗𝑚)𝑇 given by
𝐸0 = ((1 − 𝑤1) 𝜇𝑓 + 𝜃𝑢1 + 𝜇𝑓 + 𝜃 , 0, 0,
𝑤1𝜇𝑓 + 𝑢1𝑢1 + 𝜇𝑓 + 𝜃 ,
(1 − 𝑤2) 𝜇𝑚 + 𝜃𝑢2 + 𝜇𝑚 + 𝜃 , 0,




In order to compute the basic reproduction number, we
need the following components. During his infection period,(𝛾𝑚 + 𝜇𝑚)−1, an infectious male produces on average 𝛽𝑚[𝑆∗𝑓 +𝜖𝑉∗𝑓 ] infections in females. Therefore,
𝑇𝑓𝑚 = 𝛽𝑚 (𝑆
∗
𝑓 + 𝜖𝑉∗𝑓 )𝛾𝑚 + 𝜇𝑚 (7)
is the infection transfer from infectious males to females. An
infectious female aware of her infection produces on average𝛽𝑓(𝑆∗𝑚 + 𝜖𝑉∗𝑚) infections during her infectious period (𝛾𝑓 +𝜇𝑓)−1. As a result,
𝑇𝑚𝐼𝑓 = 𝛽𝑓 (𝑆
∗
𝑚 + 𝜖𝑉∗𝑚)𝛾𝑓 + 𝜇𝑓 (8)
is the infection transfer from the aware infectious females to
males. Analogously,
𝑇𝑚𝑈𝑓 = 𝛽𝑓 (𝑆
∗
𝑚 + 𝜖𝑉∗𝑚)𝛾𝑓 + 𝛼 + 𝜇𝑓 (9)
is the infection transfer from the unaware infectious females
to males. Moreover, a fraction 𝛼/(𝛾𝑓 + 𝛼 + 𝜇𝑓) of unaware
infected females becomes aware of the infection via screen-
ing; thus




is the infection transfer from females to males.




0 0 (1 − 𝑝) 𝑇𝑓𝑚
0 0 𝑝𝑇𝑓𝑚







it can be shown that the basic reproduction numberR0 is the
geometric mean of the terms 𝑇𝑓𝑚 and 𝑇𝑚𝑓 ; that is,
R0 = √𝑇𝑓𝑚 ⋅ 𝑇𝑚𝑓 . (12)
As a consequence of Theorem 2 in [23], the disease-free
equilibrium 𝐸0 is locally asymptotically stable ifR0 < 1 and
unstable ifR0 > 1.
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3. The Optimal Control Problems
Five controls are possible in this modeling framework; hence,
we formulate optimal control problems incorporating these
five controls, namely:
(i) 𝑤1(⋅) and 𝑤2(⋅) are the controls representing the
fraction of females and males, respectively, that are
vaccinated prior to sexual initiation
(ii) 𝑢1(⋅) and 𝑢2(⋅) are the controls representing the vacci-
nation rates of susceptible sexually active females and
males, respectively
(iii) 𝛼(⋅) is the control representing the screening rate for
females
Because resources of a health system are limited, we assume
that all the controls are subject to constraints
0 ≤ 𝑤1 (𝑡) , 𝑤2 (𝑡) ≤ 1,
0 ≤ 𝑢1 (𝑡) , 𝑢2 (𝑡) ≤ 𝑢𝑚𝑎𝑥,
0 ≤ 𝛼 (𝑡) ≤ 𝛼𝑚𝑎𝑥.
(13)
With these controls and taking into consideration the con-
stant population size assumption, we can write model (5) as
the following system of five equations:
?̇?𝑓 = ((1 − 𝑈𝑓 − 𝐼𝑓 − 𝑉𝑓) + 𝜖𝑉𝑓) (1 − 𝑝) 𝛽𝑚𝐼𝑚
− (𝛾𝑓 + 𝛼 (𝑡) + 𝜇𝑓)𝑈𝑓,
̇𝐼𝑓 = ((1 − 𝑈𝑓 − 𝐼𝑓 − 𝑉𝑓) + 𝜖𝑉𝑓) 𝑝𝛽𝑚𝐼𝑚 + 𝛼 (𝑡) 𝑈𝑓
− (𝛾𝑓 + 𝜇𝑓) 𝐼𝑓,
?̇?𝑓 = 𝑤1 (𝑡) 𝜇𝑓 + 𝑢1 (𝑡) (1 − 𝑈𝑓 − 𝐼𝑓 − 𝑉𝑓)
− 𝜖𝛽𝑚𝑉𝑓𝐼𝑚 − (𝜇𝑓 + 𝜃)𝑉𝑓,
̇𝐼𝑚 = (𝛽𝑓𝑈𝑓 + 𝛽𝑓𝐼𝑓) ((1 − 𝐼𝑚 − 𝑉𝑚) + 𝜖𝑉𝑚)
− (𝛾𝑚 + 𝜇𝑚) 𝐼𝑚,
?̇?𝑚 = 𝑤2 (𝑡) 𝜇𝑚 − (𝛽𝑓𝑈𝑓 + 𝛽𝑓𝐼𝑓) 𝜖𝑉𝑚
+ 𝑢2 (𝑡) (1 − 𝐼𝑚 − 𝑉𝑚) − (𝜇𝑚 + 𝜃)𝑉𝑚,
(14)
complemented by initial conditions
0 ≤ 𝑈𝑓 (0) , 𝐼𝑓 (0) , 𝑉𝑓 (0) , 𝐼𝑚 (0) , 𝑉𝑚 (0) ≤ 1. (15)
The set of admissible controls 𝐷(𝑇) is the set of Lebesgue
measurable functions (𝑤1(⋅), 𝑤2(⋅), 𝑢1(⋅), 𝑢2(⋅), 𝛼(⋅))𝑇 which
for almost all 𝑡 ∈ [0, 𝑇] satisfy constraints (13).
We seek the optimal controls that reduce the incidence
and prevalence of the infection and also the cost of using a
public health intervention over 𝑇 years. In the case where
the elimination of HPV infection is not possible due to social
or economic constraints, the public health system can focus,
instead, on the protection of the vulnerable group, that is, on
minimizing the number of cervical cancer cases and related
diseases in females over the time interval [0, 𝑇]. For this case,
the objective functional is
𝐽 = ∫𝑇
0
(𝐴0 (𝑈𝑓 + 𝐼𝑓) + 12 [𝐴1 (𝑤21 + 𝑤22)
+ 𝐴2 (𝑢21 + 𝑢22) + 𝐴3𝛼2]) 𝑑𝑡.
(16)
Secondly, having the aim of the ultimate elimination of the
infection inmind,we consider the problemofminimizing the
total prevalence 𝑃(𝑡) = 𝑈𝑓(𝑡) + 𝐼𝑓(𝑡) + 𝐼𝑚(𝑡) at the terminal
timemoment𝑇. In this context, the objective functional takes
the following form:
𝐽 = 𝐴0𝑃 (𝑇) + 12
⋅ ∫𝑇
0
(𝐴1 (𝑤21 + 𝑤22) + 𝐴2 (𝑢21 + 𝑢22) + 𝐴3𝛼2) 𝑑𝑡.
(17)
In these functionals, the parameter 𝐴0 balances the proba-
bility of developing cervical cancer and its treatment cost,
whereas𝐴0 reflects the cost of the long-termpresence ofHPV
infection in the population. The meaning of the parameters𝐴1, 𝐴2, and 𝐴3 in both functionals is the same. Specifically,
the weight parameter 𝐴1 represents the cost associated with
the vaccination of school girls and boys prior to their sexual
initiation. The weight parameter 𝐴2 represents the cost of
administering the vaccine in sexually active individuals.
Finally, 𝐴3 represents the cost of screening and follow-up
after an abnormal Pap test.
We are assuming that the cost of applying health poli-
cies increases as a nonlinear function of the controls. The
quadratic terms penalize high levels of control administra-
tion in comparison with the cost of low levels. Due to its
mathematical convenience, the sum of the weighted squares
of the controls is probably the most common form of the
objective functional in the literature: for functionals of this
type, it is possible to reduce an optimal control problem
to a two-point boundary value problem. Furthermore, for
such functionals, the optimal controls can be obtained as
explicit functions of the state and adjoint variables via the
Pontryagin maximum principle. Although the financial cost
of public health interventions to prevent epidemics most
likely grows linearly with themagnitude of the corresponding
control [24], we choose objective functionals with a quadratic
dependence on the controls following the current trend of the
literature [17, 18, 25–27].
4. The Pontryagin Maximum Principle
For control model (14) and the set of admissible controls𝐷(𝑇), we can formulate two different optimal control prob-
lems using the objective functionals (16) and (17). Here, we
prove the existence of solutions for these optimal control
problems and we also obtain the optimality system in order
to find a numerical approximation of the optimal controls.
Let us introduce the states 𝑥 = (𝑈𝑓, 𝐼𝑓, 𝑉𝑓, 𝐼𝑚, 𝑉𝑚)𝑇
and the controls 𝑐 = (𝑤1, 𝑤2, 𝑢1, 𝑢2, 𝛼)𝑇 and denote the
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right-hand side of the control model (14) as the vector
function 𝐹(𝑡, 𝑥, 𝑐). For the objective functional (16), the
optimal control problem of the HPV epidemic model is
min
𝑐∈𝐷(𝑇)




𝐿 (𝑡, 𝑥 (𝑡) , 𝑐 (𝑡)) (18)
where
𝐿 (𝑡, 𝑥, 𝑐)
= 𝐴0 (𝑈𝑓 + 𝐼𝑓)
+ 12 (𝐴1 (𝑤21 + 𝑤22) + 𝐴2 (𝑢21 + 𝑢22) + 𝐴3𝛼2)
(19)
subject to the dynamics of the control model (14) with given
initial conditions.
We call a pair of states and controls (𝑥, 𝑐) satisfying both
(14) and 𝑐 ∈ 𝐷(𝑇) a feasible pair. Theorem 4.1 in [28,
Chapter III] ensures the existence of an optimal control and
the corresponding solution for this problem. In particular,
this existence theorem states that the following conditions are
sufficient to guarantee the existence of an optimal control for
(14):
(H1) 𝐹 is continuous, and there exist positive constants 𝐾1
and 𝐾2 such that
(a) |𝐹(𝑡, 𝑥, 𝑐)| ≤ 𝐾1(1 + |𝑥| + |𝑐|)
(b) |𝐹(𝑡, 𝑥, 𝑐) − 𝐹(𝑡, 𝑥, 𝑐)| ≤ 𝐾2|𝑥 − 𝑥|(1 + |𝑐|)
hold for all 𝑡 ∈ [0, 𝑇].Moreover,𝐹 can bewritten
as 𝐹(𝑡, 𝑥, 𝑐) = 𝜙(𝑡, 𝑥) + 𝜓(𝑡, 𝑥)𝑐
(H2) The set of admissible controls 𝐷(𝑇) is closed and
convex. Moreover, there is at least one feasible pair(𝑥(𝑡), 𝑐(𝑡)) satisfying both (14) and (13)
(H3) 𝐿(𝑡, 𝑥, ⋅) is convex on 𝐷(𝑇), and 𝐿(𝑡, 𝑥, 𝑐) ≥ 𝐾3|𝑐|𝛽 −𝐾4, 𝐾3 > 0, 𝐾4 ∈ R, 𝛽 > 1
Theorem 1. Consider the optimal control problem with control
model (14) and cost functional (16). Then there exist 𝑐∗ =(𝑤∗1 , 𝑤∗2 , 𝑢∗1 , 𝑢∗2 , 𝛼∗) ∈ 𝐷(𝑇) such that min 𝐽(𝑐)𝑐∈𝐷(𝑇) = 𝐽(𝑐∗).
Proof. Due to the a priori boundedness of the solutions
of the control model (14) and the differentiability of the
function 𝐹, it follows that (a) and (b) in (H1) are ensured
by suitable bounds on the partial derivatives of 𝐹 and on𝐹(𝑡, 0, 0). Moreover, the state equations are linear with respect
to the controls 𝑐, and thus 𝐹(𝑡, 𝑥, 𝑐) = 𝜙(𝑡, 𝑥) + 𝜓(𝑡, 𝑥)𝑐. The
existence of a feasible pair is guaranteed by the Caratheodory
theorem [29, pp. 182] for initial value problems. Moreover,
for bounded controls on a finite time interval,𝐷(𝑇) is clearly
closed and convex, and, hence, (H2) is satisfied as well. The
integrand (19) of the cost functional is positive and quadratic
with respect to the controls; therefore, 𝐿(𝑡, 𝑥, ⋅) is convex on𝐷(𝑇). Furthermore, defining 𝐾3 = min{𝐴1, 𝐴2, 𝐴3}, we have𝐿(𝑡, 𝑥, 𝑐) ≥ (1/2)𝐾3|𝑐|2, thus verifying (H3) and completing
the proof.
Our next aim is to obtain the so-called optimality system
in order to find numerically optimal controls 𝑤∗1 (𝑡), 𝑤∗2 (𝑡),𝑢∗1 (𝑡), 𝑢∗2 (𝑡), 𝛼∗(𝑡). We define the Hamiltonian
𝐻 = 𝐿 (𝑡, 𝑥, 𝑐) + 𝜓1?̇?𝑓 + 𝜓2 ̇𝐼𝑓 + 𝜓3?̇?𝑓 + 𝜓4 ̇𝐼𝑚
+ 𝜓5?̇?𝑚. (20)
By the Pontryaginmaximumprinciple [28], given the optimal
control 𝑐∗(⋅) that minimizes the Hamiltonian (20) for almost
all 𝑡 ∈ [0, 𝑇] and the corresponding optimal solutions 𝑥(𝑡) =(𝑈𝑓(𝑡), 𝐼𝑓(𝑡), 𝑉𝑓(𝑡), 𝐼𝑚(𝑡), 𝑉𝑚(𝑡))𝑇, there are adjoint variables𝜓𝑖 that satisfy the system
?̇?1 = −𝐴0 + [(1 − 𝑝) 𝛽𝑚𝐼𝑚 + 𝛾𝑓 + 𝛼∗ + 𝜇𝑓] 𝜓1
+ (𝑝𝛽𝑚𝐼𝑚 − 𝛼∗) 𝜓2 + 𝑢∗1𝜓3
− 𝛽𝑓 [(1 − 𝐼𝑚 − 𝑉𝑚) + 𝜖𝑉𝑚] 𝜓4 + 𝛽𝑓𝜖𝑉𝑚𝜓5,
?̇?2 = −𝐴0 + (1 − 𝑝) 𝛽𝑚𝐼𝑚𝜓1 + (𝑝𝛽𝑚𝐼𝑚 + 𝛾𝑓 + 𝜇𝑓)𝜓2
+ 𝑢∗1𝜓3 − 𝛽𝑓 [(1 − 𝐼𝑚 − 𝑉𝑚) + 𝜖𝑉𝑚] 𝜓4
+ 𝛽𝑓𝜖𝑉𝑚𝜓5,
?̇?3 = [(1 − 𝑝) 𝜓1 + 𝑝𝜓2] (1 − 𝜖) 𝛽𝑚𝐼𝑚
+ (𝜖𝛽𝑚𝐼𝑚 + 𝑢∗1 + 𝜇𝑓 + 𝜃)𝜓3,
?̇?4 = −𝛽𝑚 ((1 − 𝑈𝑓 − 𝐼𝑓 − 𝑉𝑓) + 𝜖𝑉𝑓)
⋅ [(1 − 𝑝) 𝜓1 + 𝑝𝜓2] + 𝜖𝛽𝑚𝑉𝑓𝜓3
+ (𝛽𝑓𝑈𝑓 + 𝛽𝑓𝐼𝑓 + 𝛾𝑚 + 𝜇𝑚) 𝜓4 + 𝑢∗2𝜓5,
?̇?5 = (𝛽𝑓𝑈𝑓 + 𝛽𝑓𝐼𝑓) ((1 − 𝜖) 𝜓4 + 𝜖𝜓5)
+ (𝑢∗2 + 𝜃 + 𝜇𝑚) 𝜓5,
(21)
with the corresponding conditions 𝜓𝑖(𝑇) = 0 for 𝑖 = 1, . . . , 5.
From the optimality conditions, we obtain the following
characterization for the optimal controls:
𝑤∗1 (𝑡) = min{1,max{0, − 𝜇𝑓𝐴1𝜓3 (𝑡)}} ,
𝑤∗2 (𝑡) = min{1,max{0, −𝜇𝑚𝐴1𝜓5 (𝑡)}} ,
𝑢∗1 (𝑡)
= min{𝑢𝑚𝑎𝑥,max{0, − 1𝐴2 (1 − 𝑈𝑓 (𝑡) − 𝐼𝑓 (𝑡) − 𝑉𝑓 (𝑡)) 𝜓3 (𝑡)}} ,
𝑢∗2 (𝑡)
= min{𝑢𝑚𝑎𝑥,max{0, − 1𝐴2 (1 − 𝐼𝑚 (𝑡) − 𝑉𝑚 (𝑡)) 𝜓5 (𝑡)}} ,
𝛼∗ (𝑡)
= min{𝛼𝑚𝑎𝑥,max{0, 1𝐴3 (𝜓1 (𝑡) − 𝜓2 (𝑡)) 𝑈𝑓 (𝑡)}} .
(22)
The proof of the existence of solutions for the optimal
control problemwith the objective functional (17) follows the
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Table 1: Parameters values of the control model (14) used in the simulations.
Parameter Range Mean Value Units Source
1 − 𝜖 [0.8, 1] 0.9 adimensional [3]
1/𝜃 [5, 15] 10 year [19]
𝛽𝑚 [0.05, 5] 4.0 year−1 [3]𝛽𝑓 [0.05, 5] 4.0 year−1 [3]𝛽𝑓 [0.025, 2.5] 2.0 year−1 Estimated1/𝛾𝑓 [0.83, 2] 1.3 year [20]1/𝛾𝑚 [0.33, 1.2] 0.6 year [21]𝑝 [0, 1] 0.2 adimensional Estimated
1/𝜇𝑓 [15, 50] 30 year Estimated1/𝜇𝑚 [15, 50] 30 year Estimated
same reasoning as inTheorem 1 and is, therefore, omitted.The
technical details for the computation of the optimality system
and characterization of the optimal control associated with
objective functional (17) are provided in the appendix.
5. Results
We start by exploring the control model (14) numerically.
The optimal control solutions can be obtained solving the
optimality system. In order to obtain approximations of
our optimality systems, we use the forward-backward sweep
method (FBSM) from [30].This iterative scheme begins with
an initial guess on the controls; then, the state equations are
solved forward in time. After that, since the transversality
conditions for our problems are posed at the final time 𝑇, the
system for the adjoint variables is solved backward in time.
The controls are updated using a convex combination of the
previous controls and the new control obtained substituting
the states and adjoints into its characterization. This process
is repeated until convergence criteria are satisfied. For solving
the state and adjoint systems, we use a fourth order Runge-
Kutta scheme.
5.1. Model Parameters. Parameters values, units, and source
of estimation are summarized in Table 1. We use these values
unless otherwise is stated. Next, we outline their selection:
(i) Vaccine efficacy, 1 − 𝜖. Although clinical trials are
still underway, there is evidence indicating efficacy
of around 90% for the nonavalent HPV vaccine
Gardasil-9 [3]. We set 1 − 𝜖 ∈ [0.8, 1].
(ii) Vaccine protection, 1/𝜃. The exact duration of vaccine
protection is unknown, but clinical trials [19] have
shown sustained efficacy for more than 5 years. We
assume that the protection is from 5 to 15 years; thus1/𝜃 ∈ [5, 15] years.
(iii) Transmission rates,𝛽𝑚,𝛽𝑓, and𝛽𝑓. Transmission rates
are the product of the average number of sexual con-
tacts per unit of time and the probability of infection
transfer per contact. We assume that both genders
have between 1 and 5 sexual partners per year and per-
act transmission probability range 5−100%[3].We set𝛽𝑖 ∈ [0.05, 5] 𝑦𝑒𝑎𝑟−1 with 𝑖 ∈ {𝑓,𝑚}. We also assume
that the aware infected females take measures, such as
condom use, that decrease the probability of infection
transfer. Thus 𝛽𝑓 ∈ [0.025, 2.5] 𝑦𝑒𝑎𝑟−1.
(iv) Females’ infectious period, 1/𝛾𝑓.Themean duration of
a new genital HPV infection in women is 14.8 months
for oncogenic types and 11.1months for nononcogenic
types [20]. Since the majority of the types targeted by
Gardasil-9 are oncogenic, we assume that the female
infectious period is between 9 months and 2 years;
thus 1/𝛾𝑓 ∈ [0.83, 2] 𝑦𝑒𝑎𝑟.
(v) Male’s infectious period, 1/𝛾𝑚. For men, most of the
HPV infections clear in less than 12 months. Studies
(see [21] and the references therein) report average
clearance time of 5.9 to 7.5 months. We set 1/𝛾𝑚 ∈[0.33, 1.2] year.
(vi) Fraction of females that become aware of their infec-
tion, 𝑝. Since 𝑝 is a fraction, 𝑝 ∈ [0, 1].
(vii) Periods of sexual activity, 1/𝜇𝑓, and 1/𝜇𝑚. We assume
that the average duration of the sexual activity period
for both, males and females, is between 15 and 50
years; therefore 𝜇−1𝑓 , 𝜇−1𝑚 ∈ [15, 50] years.
Estimates of weight parameters associated with the ob-
jective functionals exhibit considerable variability in the
literature. Thus, in the numerical simulations, several com-
binations of weight parameters are explored.
5.2. Uncontrolled System and Constant Control. In order to
demonstrate the importance of the optimal controls, we firstly
show the behavior of the model in the absence of control and
under constant controls. The results are shown in Figure 1. It
is easy to see that, without control, the system converges to
an endemic equilibrium state (see Figure 1(a)).With constant
controls (see Figure 1(b)) the infectious cases are reduced but
the infection is not eradicated for this time interval. Besides,
the number of vaccinated individuals tends to a very high
proportion.
5.3. Optimal Vaccination and Screening. For the numerical
computation of the optimal controls, we should complement
the fixed parameters in Table 1 with values for the weights in
the objective functionals. The cost of the nonavalent vaccine
Abstract and Applied Analysis 7










































Figure 1: Behavior ofmodel (14) in the absence of controls (a) andwith constant controls (b). In case (b), the values of controls are𝑤1(𝑡) = 0.2,𝑤2(𝑡) = 0.1, 𝑢1(𝑡) = 0.5, 𝑢2(𝑡) = 0.2, and 𝛼(𝑡) = 0.2 for all 𝑡. The initial conditions are 𝑈𝑓(0) = 0.05, 𝐼𝑓(0) = 0.05, 𝑉𝑓(0) = 0.1, 𝐼𝑚(0) = 0.1,
and 𝑉𝑚(0) = 0.05.









































Figure 2: Solution (a) and the optimal controls (b) of the control model (14) with objective functional (16) and weight parameters 𝐴0 = 1,𝐴1 = 3, 𝐴2 = 10, and 𝐴3 = 3. Here, the initial conditions are𝑈𝑓(0) = 0.05, 𝐼𝑓(0) = 0.05, 𝑉𝑓(0) = 0.1, 𝐼𝑚(0) = 0.1, and 𝑉𝑚(0) = 0.05.
Gardasil-9 is approximately $134.26 per dose [18]. However,
the associated weight parameters in functionals (16) and (17),
namely, 𝐴1 and 𝐴2, also include costs attributable to vaccine
distribution, storage, and other administration-associated
costs. It can be expected that administering the vaccine in
school preadolescents is less expensive than vaccination of
the sexually active adults; that is, 𝐴1 < 𝐴2 [17]. Note also
that the weights 𝐴0 and 𝐴0 are related to the cost of having
infected individuals for this; they are different from weights𝐴1,𝐴2,𝐴3 which reflect the cost of the control interventions.
Thus, the values of𝐴0 and𝐴0 and their rations to𝐴1,𝐴2, and𝐴3 are particularly important for the optimal controls. For
example, if 𝐴0, 𝐴0 < 𝐴1, 𝐴2, 𝐴3, that is, if treating infected
individuals (including the cost of cancer induced by HPV)
is assumed less costly than mass vaccination, then, in terms
of minimizing cost, it can be logical to stop intervention
programs. Therefore, in such a case, one can expect low
vaccination and screening rates as the optimal policies. This
consideration is confirmed by the results of the computations
shown in Figure 2 where we plotted the optimal control
corresponding to the cost functional (16) for
𝐴1𝐴0 = 3,
𝐴2𝐴0 = 10,
𝐴3𝐴0 = 3. (23)
Please, observe that for this case the magnitude of the
controls is very small (Figure 2(b)) and, consequently, the
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optimal controls are insufficient to reduce the spread of the
infection (Figure 2(a)).Therefore, in what follows, we assume
that the costs of having infected individuals are greater
than the costs of administering the vaccine and screening
programs. In particular, we assume that the values of weights𝐴0 and 𝐴0 are two or three orders of magnitude bigger than
the value of𝐴1,𝐴2, and𝐴3. As a base case, we also set 𝑢𝑚𝑎𝑥 =3 and 𝛼𝑚𝑎𝑥 = 3. Before going any further to computations,
we stress that, for problems of infectious disease control, the
initial conditions can play an important role in the search of
optimal controls. However, most studies overlook this issue.
In this paper, we consider different initial conditions and
explore how the optimal control varies depending on them.
We choose three different sets of initial conditions to reflect
precise infection levels, namely,
(i) Low prevalence levels for both females and males
(Figures 3(a), 3(b), 4(a), and 4(b))
(ii) High prevalence for females and low prevalence for
males (Figures 3(c), 3(d), 4(c), and 4(d))
(iii) Low prevalence for women and high prevalence for
males (Figures 3(e), 3(f), 4(e), and 4(f))
We start the numerical simulations considering the control
model (14) with the objective functional (16) that aims to
protect the vulnerable group. In other words, we seek to
minimize the number of infections and cervical cancer cases
in females. In this scenario, the optimal controls are charac-
terized by system (22). In Figure 3, we show the numerical
solution obtained via the FBSM. Figures 3(b), 3(d), and 3(f)
illustrate the profiles of the optimal vaccination and screening
rates, whereas Figures 3(a), 3(c), and 3(e) show the dynamics
of the state variables. For the three initial conditions, we
observe that𝑤2(𝑡) ≤ 𝑤1(𝑡) and𝑢2(𝑡) ≤ 𝑢1(𝑡).This implies that
the vaccination of females is more significant than increasing
male’s immunization coverage. Nevertheless, we remark that,
regardless of the independence of the objective functional
(16) from male prevalence, the magnitude of the vaccination
rates for males and females are nearly identical. Thus, to
a certain extent, males’ vaccination can be as important as
females’ vaccination. Furthermore, comparing Figures 3(b),
3(d), and 3(f), one can see that the optimal control profiles
for the screening and vaccination rates are qualitatively and
quantitatively similar. In other words, the optimal controls do
not depend on the initial conditions. Please note that for all
the scenarios explored, the optimal controls start with very
high vaccination rates which quickly reduce the number of
infected individuals to very low levels.These controls are then
gradually reduced in value but aremaintained enough time to
achieve the ultimate eradication of the infection.
Our next task is to investigate the profiles of the optimal
vaccination and screening rates with the cost functional (17)
that aims to minimize the total prevalence at the final time𝑇. We compute the numerical solution of the two-point
boundary value problem for the maximum principle via the
FBSM (Figure 4). It is notable that also for the functional (17),
the optimal vaccination rates for both sexes are remarkably
similar for each of the initial conditions, respectively (see
Figures 4(b), 4(d), and 4(f)). Even so, in contrast with the
controls for functional (16), this time the controls do not
start with high rates. This allows the number of infected
individuals in the population to grow during the early phase
of the epidemic. In spite of this, the optimal controls manage
to eliminate the infection at the end of the time interval.
Moreover, the infection levels in Figures 4(a), 4(c), and 4(e)
are clearly higher than those in Figures 3(a), 3(c), and 3(e),
respectively. Therefore, even though the controls for both
functionals achieve the elimination of the infection, the
controls for protection of the vulnerable group do itmore effi-
ciently. Nevertheless, there is considerably more vaccination
in this case than for the case of eradication of the infection.
Thus, the controls for functional (16) are presumably more
expensive than the controls for functional (17).
Figure 5 presents a more direct comparison of relevant
model outcomes under objective functionals (16) and (17).
Figure 5(a) shows the total infected population as function
of time under the optimal controls. Figure 5(b) shows the
function𝐴1(𝑤∗1 (𝑡)+𝑤∗2 (𝑡))+𝐴2(𝑢∗1 (𝑡)+𝑢∗2 (𝑡))+𝐴3𝛼∗(𝑡)which
represents the cost of applying the optimal controls (without
the cost of having infected individuals in the population).
Figure 5(c) shows the reproduction number in the presence
of vaccination and screeningR0 as function of time using the
time series of the optimal controls. The blue dashed lines are
the outcomes associated with functional (16) whose aim is to
protect the vulnerable group. Meanwhile, the red solid lines
are associated with functional (17) whose aim is to eradicate
the infection.
From Figure 5 it is clear that the total prevalence is lower,
for almost all times, when the objective is the protection
of the vulnerable group (Figure 5(a)). Probably, this is a
consequence of the huge difference in the magnitude of the
vaccination rates for both functionals at the beginning of the
time interval. Nevertheless, the cost of applying the control
policies is less, on average, for the objective of eradication
of the infection (Figure 5(b)). Yet, in the second half of the
time interval, there is more vaccination occurring for the
objective of eradication, resulting in greater costs for the
controls associated with functional (17). This also explains
why the value of the reproduction number R0 is less for the
objective of protection at the beginning of the time interval,
but after a while, its value increases exceeding the value of the
R0 associated with the objective of eradication (Figure 5(c)).
Finally, we stress that the cost of having infected individuals
(which is of paramount importance) is not considered in
Figure 5(b), therefore it is still uncertain which policy has the
highest cost-effectiveness under more general hypotheses.
6. Discussion and Conclusion
In this paper, we investigate the optimal control policies
against HPV infection. To address this problem, we intro-
duced a two-sex compartmental epidemic model for the
transmission dynamics of HPV in a heterosexual population.
We incorporated five controls into this model which are able
to act simultaneously. These five controls comprise all prac-
tical intervention policies used against HPV. Using the sex-
specific infection transfers that we found, we computed the
basic reproduction numberR0 in the presence of vaccination
Abstract and Applied Analysis 9















































































































Figure 3: (b, d, f) Optimal vaccination and screening rates as functions of time for the optimal control problem with cost functional (16) for30 years. Here, 𝐴0 = 103, 𝐴1 = 3, 𝐴2 = 10, and 𝐴3 = 3. (a, c, e) Behavior of the state variables for the optimal controls in the same row.
(a, b) Initial condition 𝑥1(0) = (0.05, 0.05, 0.01, 0.05, 0.01)𝑇. (c, d) Initial condition 𝑥2(0) = (0.2, 0.1, 0.01, 0.05, 0.01)𝑇. (e, f) Initial condition𝑥3(0) = (0.05, 0.05, 0.01, 0.3, 0.01)𝑇.
and screening. Using the van den Driessche theorem [23], we
established the local stability of the disease-free equilibrium
for values of R0 less than one. This stability implies that,
if initial infection levels are sufficiently low, maintaining
R0 < 1 ensures disease’s elimination and ultimate eradication
of the virus. However, such a constant control scheme is
usually a fragile strategy in a sense that it does not consider
the changing dynamics of the disease’s spread and can be
nonoptimal in terms of cost-efficacy.
A key issue in the implementation of HPV-vaccination
is whether vaccinating both sexes is more effective than
vaccinating the females only (as it is currently done in
10 Abstract and Applied Analysis



























































































































Figure 4: (b, d, f) Optimal vaccination and screening rates as functions of time for the optimal control problem with cost functional (17) for30 years. Here 𝐴0 = 103, 𝐴1 = 3, 𝐴2 = 10, and 𝐴3 = 3. (a, c, e) Behavior of the state variables for the optimal controls in the same row.
(a, b) Initial condition 𝑥1(0) = (0.05, 0.05, 0.01, 0.05, 0.01)𝑇. (c, d) Initial condition 𝑥2(0) = (0.2, 0.1, 0.01, 0.05, 0.01)𝑇. (e, f) Initial condition𝑥3(0) = (0.05, 0.05, 0.01, 0.3, 0.01)𝑇.
most countries). Moreover, although vaccinating individuals
before their potential exposure to HPV infection can be
a strategy with a positive outcome, vaccination of older
individuals may be necessary if vaccine-induced protec-
tion is not lifelong. Here, we applied the optimal control
theory to identify an effective distribution strategy for HPV-
vaccines. We considered two different optimal control prob-
lems. Firstly, we studied a rather usual problem in the
literature: minimizing the cumulative number of infected
females and the cost of intervention policies over a given
Abstract and Applied Analysis 11
















































Figure 5: Comparison of the total prevalence (a), the cost of applying the optimal control interventions (b), and the value ofR0 as function
of the optimal controls (c).The blue dashed lines are associatedwith functional (16) and the red solid lines are associated with functional (17).
Here, 𝐴0 = 𝐴0 = 103, 𝐴1 = 3, 𝐴2 = 10, 𝐴3 = 3, and the initial condition is 𝑥3(0) = (0.05, 0.05, 0.01, 0.3, 0.01)𝑇.
time interval. Such a problem corresponds to a policy that
aimed at protection of the most vulnerable group of the
population, that is, females at risk of developing invasive
cancer. Secondly, we considered the problem of minimizing
the total infection level in both sexes at the end of a given
time interval at the lowest possible costs. This problem has a
more ambitious objective, namely, the ultimate eradication of
HPV. Such a goal is possible if the basic reproduction number
is comparatively low. The possibility of total eradication
of cervical cancer worldwide is currently discussed in the
scientific community [31].
Results of our numerical simulations show that vaccina-
tion should be administered both prior and after the sexual
debut and in both, females and males. For both functionals,
the simulations support the intuitively expected outcome
that females’ vaccination should be the priority; however, at
the same time, we show that males’ vaccination is almost
as beneficial and required. If the objective is to protect
the vulnerable group, the numerical experiments imply that
initially, higher vaccination rates should be applied which can
gradually be reduced. This policy leads to a fast reduction
in the number of infectious individuals. For the objective of
eradication of the infection, the optimal controls begin at low
rates allowing the prevalence to increase. Yet, the optimal
vaccination and screening rates increase over time achieving
the elimination of the infection at the end of the time interval.
We have to stress that our results differ from the majority
of previous studies where the suggested preferred strategy
was the vaccination of the preadolescent females prior to
their sexual initiation. We believe that such a preference for
the young females’ vaccination that prevails in the literature
arose because the majority of authors did not consider the
problem of HPV control as an optimal control problem.
This also implies that the “young females only” vaccination
is neither the optimal nor the most cost-effective policy.
Furthermore, the efficacy of an HPV reduction programmay
also depend on the actual vaccine coverage. Our results were
obtained for initially low vaccine coverage. This corresponds
to a setting where HPV vaccination is just being introduced.
Nevertheless, due to a possible nonlinear growth of the costs
with respect to the fraction of the vaccinated individuals, even
if the vaccination coverage of females is already high, it may
still be cost-effective to include males into the vaccination
program. Besides, there can be a group who is negligent or
reluctant towards the vaccination; thus, a 100% vaccination
coverage can be difficult to achieve even in one sex. Finally,
we like to note that the impacts of vaccine coverage on the
profiles of the optimal vaccination rates and the dependency
of principal properties of the controls on the forms of
objective functionals remain open questions and deserve
further study.
Appendix
Here, we compute the adjoint system and the characterization
of the optimal controls considering the objective functional
(17):
𝐽 (𝑐) = 𝐴0𝑃 (𝑇) + 12
⋅ ∫𝑇
0
(𝐴1 (𝑤21 + 𝑤22) + 𝐴2 (𝑢21 + 𝑢22) + 𝐴3𝛼2) 𝑑𝑡.
(A.1)





subject to the dynamics of the control model (14) with given
initial conditions.
The Pontryagin maximum principle converts the optimal
control problem (A.2) into a problem of minimizing point-
wise the Hamiltonian
?̃? = 12 [𝐴1(𝑤21 + 𝑤22 + 𝐴2 (𝑢21 + 𝑢22) + 𝐴3𝛼2]
+ 𝜓1?̇?𝑓 + 𝜓2 ̇𝐼𝑓 + 𝜓3?̇?𝑓 + 𝜓4 ̇𝐼𝑚 + 𝜓5?̇?𝑚
(A.3)
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with respect to the controls. Here, 𝜓𝑖 for 𝑖 = 1, . . . , 5 are
adjoint variables that satisfy the system of differential equa-
tions
?̇?1 = [(1 − 𝑝) 𝛽𝑚𝐼𝑚 + 𝛾𝑓 + 𝛼∗ + 𝜇𝑓] 𝜓1
+ (𝑝𝛽𝑚𝐼𝑚 − 𝛼∗) 𝜓2 + 𝑢∗1𝜓3
− 𝛽𝑓 [(1 − 𝐼𝑚 − 𝑉𝑚) + 𝜖𝑉𝑚] 𝜓4 + 𝛽𝑓𝜖𝑉𝑚𝜓5,
?̇?2 = (1 − 𝑝) 𝛽𝑚𝐼𝑚𝜓1 + (𝑝𝛽𝑚𝐼𝑚 + 𝛾𝑓 + 𝜇𝑓)𝜓2
+ 𝑢∗1𝜓3 − 𝛽𝑓 [(1 − 𝐼𝑚 − 𝑉𝑚) + 𝜖𝑉𝑚] 𝜓4
+ 𝛽𝑓𝜖𝑉𝑚𝜓5,
?̇?3 = [(1 − 𝑝) 𝜓1 + 𝑝𝜓2] (1 − 𝜖) 𝛽𝑚𝐼𝑚
+ (𝜖𝛽𝑚𝐼𝑚 + 𝑢∗1 + 𝜇𝑓 + 𝜃)𝜓3,
?̇?4 = −𝛽𝑚 ((1 − 𝑈𝑓 − 𝐼𝑓 − 𝑉𝑓) + 𝜖𝑉𝑓)
⋅ [(1 − 𝑝) 𝜓1 + 𝑝𝜓2] + 𝜖𝛽𝑚𝑉𝑓𝜓3
+ (𝛽𝑓𝑈𝑓 + 𝛽𝑓𝐼𝑓 + 𝛾𝑚 + 𝜇𝑚)𝜓4 + 𝑢∗2𝜓5,
?̇?5 = (𝛽𝑓𝑈𝑓 + 𝛽𝑓𝐼𝑓) ((1 − 𝜖) 𝜓4 + 𝜖𝜓5)
+ (𝑢∗2 + 𝜃 + 𝜇𝑚) 𝜓5,
(A.4)
with transversality conditions 𝜓𝑖(𝑇) = 𝐴0 for 𝑖 = 1, 2, 4, and𝜓𝑘(𝑇) = 0 for 𝑘 = 3, 5. For this control problem, applying
the maximum principle from [32], we obtain the following
characterization for the optimal controls:
𝑤∗1 (𝑡) = min{1,max{0, − 𝜇𝑓𝐴1𝜓3 (𝑡)}} ,
𝑤∗2 (𝑡) = min{1,max{0, −𝜇𝑚𝐴1𝜓5 (𝑡)}} ,
𝑢∗1 (𝑡)
= min{𝑢𝑚𝑎𝑥,max{0, − 1𝐴2 (1 − 𝑈𝑓 (𝑡) − 𝐼𝑓 (𝑡) − 𝑉𝑓 (𝑡)) 𝜓3 (𝑡)}} ,
𝑢∗2 (𝑡)
= min{𝑢𝑚𝑎𝑥,max{0, − 1𝐴2 (1 − 𝐼𝑚 (𝑡) − 𝑉𝑚 (𝑡)) 𝜓5 (𝑡)}} ,
𝛼∗ (𝑡)
= min{𝛼𝑚𝑎𝑥,max{0, 1𝐴3 (𝜓1 (𝑡) − 𝜓2 (𝑡)) 𝑈𝑓 (𝑡)}} .
(A.5)
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findings of this study are available from the corresponding
author upon request.
Conflicts of Interest
The authors declare that they have no conflicts of interest.
Acknowledgments
Fernando Saldaña acknowledges the support by CONACyT,
Mexico, under grant number 331294. Andrei Korobeinikov
is supported by Spain’s Ministerio de Ciencia, Innovación y
Universidades grant MTM2015-71509-C2-1-R.
References
[1] WHO, “Cervical cancer,” 2018, https://www.who.int/cancer/
prevention/diagnosis-screening/cervical-cancer/en/.
[2] FDA, “Fda approves expanded use of gardasil-9 to include indi-
viduals 27 through 45 years old,” 2018, https://bit.ly/2zVRxa9.
[3] M. Brisson, J.-F. Laprise, H. W. Chesson et al., “Health and
economic impact of switching from a 4-valent to a 9-valent
hpv vaccination program in the united states,” Journal of the
National Cancer Institute, vol. 108, no. 1, 2016.
[4] K. Seto, F. Marra, A. Raymakers, and C. A. Marra, “The cost
effectiveness of human papillomavirus vaccines: a systematic
review,”Drugs, vol. 72, no. 5, pp. 715–743, 2012.
[5] G. P. Garnett, J. J. Kim, K. French, and S. J. Goldie, “Chapter 21:
Modelling the impact of HPV vaccines on cervical cancer and
screening programmes,” Vaccine, vol. 24, no. 3, pp. S178–S186,
2006.
[6] A. T. Newall, P. Beutels, J. G. Wood, W. J. Edmunds, and C.
R. MacIntyre, “Cost-effectiveness analyses of human papillo-
mavirus vaccination,”The Lancet Infectious Diseases, vol. 7, no.
4, pp. 289–296, 2007.
[7] E. H. Elbasha, E. J. Dasbach, and R. P. Insinga, “Model for
assessing human papillomavirus vaccination strategies,” Emerg-
ing Infectious Diseases, vol. 13, no. 1, pp. 28–41, 2007.
[8] J. J. Kim and S. J. Goldie, “Cost effectiveness analysis of includ-
ing boys in a human papillomavirus vaccination programme
in the United States,” British Medical Journal, vol. 339, article
b3884, 2009.
[9] E. H. Elbasha and E. J. Dasbach, “Impact of vaccinating boys
andmen against HPV in the United States,”Vaccine, vol. 28, no.
42, pp. 6858–6867, 2010.
[10] M. A. Smith, J.-B. Lew, R. J. Walker, J. M. L. Brotherton,
C. Nickson, and K. Canfell, “The predicted impact of HPV
vaccination on male infections and male HPV-related cancers
in Australia,” Vaccine, vol. 29, no. 48, pp. 9112–9122, 2011.
[11] J. A. Bogaards, M. Kretzschmar, M. Xiridou, C. J. L. M. Meijer,
J. Berkhof, and J. Wallinga, “Sex-specific immunization for
sexually transmitted infections such as human papillomavirus:
insights from mathematical models,” PLoS Medicine, vol. 8, no.
12, article e1001147, 2011.
[12] T. Malik, J. Reimer, A. Gumel, E. Elbasha, and S. Mahmud,
“The impact of an imperfect vaccine andPap cytology screening
on the transmission of human papillomavirus and occurrence
of associated cervical dysplasia and cancer,” Mathematical
Biosciences and Engineering, vol. 10, no. 4, pp. 1173–1205, 2013.
[13] A. A. Alsaleh and A. B. Gumel, “Analysis of risk-structured
vaccination model for the dynamics of oncogenic and warts-
causing HPV types,” Bulletin of Mathematical Biology, vol. 76,
no. 7, pp. 1670–1726, 2014.
[14] A.M. Guerrero, A. J. Genuino,M. Santillan et al., “A cost-utility
analysis of cervical cancer screening and human papillomavirus
vaccination in the Philippines,” BMC Public Health, vol. 15, no.
1, article 730, 2015.
Abstract and Applied Analysis 13
[15] F. Saldaña and I. Barradas, “The role of behavioral changes
and prompt treatment in the control of STIs,” Infectious Disease
Modelling, vol. 4, pp. 1–10, 2019.
[16] O. Sharomi and T. Malik, “Optimal control in epidemiology,”
Annals of Operations Research, vol. 251, no. 1-2, pp. 55–71, 2017.
[17] V. L. Brown and K. A. Jane White, “The role of optimal
control in assessing the most cost-effective implementation of
a vaccination programme: HPV as a case study,” Mathematical
Biosciences, vol. 231, no. 2, pp. 126–134, 2011.
[18] T. Malik, M. Imran, and R. Jayaraman, “Optimal control with
multiple human papillomavirus vaccines,” Journal ofTheoretical
Biology, vol. 393, pp. 179–193, 2016.
[19] W. K. Huh, E. A. Joura, A. R. Giuliano et al., “Final efficacy,
immunogenicity, and safety analyses of a nine-valent human
papillomavirus vaccine in women aged 16–26 years: a ran-
domised, double-blind trial,”The Lancet, vol. 390, no. 10108, pp.
2143–2159, 2017.
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